Русский
Nederlandse taal
Deutsch
Francés
한국어
Português
Español
日本語
ไทย
Deep Cross Linked Hyaluronic Acid Deep Type
Ingredient: 24mg/m hyaluronic acid
Specification: 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml
Package: Syringe
Recommended use: 1-3pcs, 12 months apart
Application Area: Chin, nasal dorsum, nasal column and anterior nose
Product Introduction：
Innovative cross linking technology yields two gel systems: Single gels mimic natural tissue seamlessly, whereas double variants provide robust lifting with minimal extrusion force. Our tiered product matrix (Sub-skin to Micro) enables precision treatments - D12's micro-crosslinked structure prevents pico formation in delicate areas, while HD20's crimson hue and vitamin complex optimize lip revitalization. Comparative analyses reveal extended durability and 18% lower elastic modulus versus competitors.
Product Display：
Product Details:
Type | Deep |
Ingredient | Cross Linked Hyaluronic Acid Dermal Filler |
Specification | 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml |
Cross Link | BDDE chemical cross link |
Texture | Gel |
Elasticity | 500 Pa-650 Pa |
Viscosity | 150 Pa-250 Pa |
Mean particle size | 400μm-600μm |
Effective content | 24mg/mL |
Cross linker residue | No,or≤0.5ug/g |
Protein residue | ≤20μg/g |
Endotoxin content | <0.5EU/mL |
Swelling degree | 20-40 |
Extruding force | 20N-30N |
Application area | Chin, nasal dorsum, nasal column and anterior nose |
Package | Syringe |
Stoarge | Room temperature (1-25ºC), cool and dry place |
Recommended | 1-3 pcs (vary with each individual |
Recommended interval | 12 month |
Product Package:
Customer Feedback:
Raw Material Advantages：
1.CLHA hydrogels maintain structural stability across physiological pH ranges (4.0-9.0) for versatile clinical applications.
2.Cross-linking technology enables development of high-G' products for subdermal implantation with minimal deformation risk.
Development Process:
Company Introduction:
Jinan Grandwill Medical Technology merges cutting-edge R&D with precision manufacturing. Established in 2014, we hold regulatory approvals for 1 Class III absorbable hemostat and 4 Class II medical devices. Our state-of-the-art facility integrates microbial testing labs, freeze-drying systems, and BFS technology, supported by 11 patents. Rigorous sterilization protocols and FDA/CE compliance guarantee non-toxic, residue-free products for global healthcare markets.
